Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|16/03/2018||Race increases placement to $3.69m||Download|
|12/03/2018||Race completes over-subscribed $3.159 million placement||Download|
|27/02/2018||Section 708A Notice||Download|
|21/02/2018||Second Bisantrene Patent Allowed in US||Download|
|20/02/2018||Appendix 4D & Half-Year Financial Statements||Download|